Category: Biotech

November 30, 2023

Flagship Pioneering is looking to raise $3 billion for its eighth venture fund, a sign the high-profile company creator continues to see investor interest in the biotechnology sector despite a turbulent market. The plans were outlined in a securities document […]

October 30, 2023

For years, many of the world’s largest, most deep-pocketed pharmaceutical firms had cast brain drugs aside, opting instead to devote resources to less risky, often more lucrative areas of research like oncology and immunology. But recent scientific and technological breakthroughs, […]

October 26, 2023

Despite optimism for a stronger investment climate this year, many of the hurdles that faced young biotechnology companies in late 2022 have endured through 2023. Initial public offerings for drugmakers have remained slow, with only 18 biotechs making their public […]

October 24, 2023

When developing new medicines, drugmakers typically try to make treatments that are more effective, durable or safer than what’s already available. If they’re lucky, they can hit on something that meets at least one of those goals. Rampart Bioscience, a […]

October 3, 2023

Initial public offerings may slowly be coming back to the biotechnology sector. Eight biotech companies priced IPOs from July through the end of September, raising $1.1 billion in total, according to data compiled by BioPharma Dive. That compares to four […]

September 7, 2023

Seagen is the biotech sector’s leading developer of antibody-drug conjugates, which deliver cell-killing toxins to diseased cells by attaching them to an antibody that seeks out proteins on tumor cells. Its first, Adcetris, is on track to become a blockbuster […]

August 11, 2023

The success of cancer immunotherapies like Merck & Co.’s Keytruda and Bristol Myers’ Opdivo kicked off a broad search by biopharmaceutical companies for other ways to turn the immune system against cancer. One strategy that drew interest was targeting a […]

July 29, 2023

Investors are much more cautious about the biotechs they back than they were during the sector’s peak a few years ago. Gone are the days when biotechs could easily raise cash and quickly pivot to public markets before starting a […]

July 11, 2023

While much of corporate America rethinks its investment in physical offices, biotechnology companies are still wedded to laboratories and research facilities. Onyx Equities, which earlier this year bought Merck & Co.’s former Kenilworth, New Jersey headquarters, is counting on that […]

July 6, 2023

Initial public offerings in the biotechnology sector have been occuring at a snail’s pace in 2023, prolonging a downturn that’s now lasted nearly two years. Since January, only nine biotech companies have gone public, putting new stock offerings in the […]

June 28, 2023

This afternoon at 2 pm CET (8 am EDT), Bayer AG will host its Pharmaceuticals R&D Event 2023 for Investors. The company will present a deep dive on the innovation strategy in its four therapeutic core areas Oncology, Cardiovascular Diseases, […]

May 12, 2023

Cyclerion formed in April 2019 as a spinoff of Ironwood Pharmaceuticals. Its research revolved around therapies that stimulate sGC, or soluble guanylate cyclase, an enzyme that had already attracted interest from drugmakers as a target for heart and lung diseases. […]

April 14, 2023

Backed by big-name investors, well-known executives and millions of dollars, a freshly launched biotechnology company hopes to turn research from a California lab into new cancer therapies. Named TORL BioTherapeutics, the company is built around discoveries from the lab of […]

April 10, 2023

At least five dozen biotechnology companies have laid off employees so far this year in a sector-wide contraction that has reached large and small drugmakers alike. Brought on by enduring funding challenges, the consolidation has resulted in roughly 3,200 biotech […]

March 24, 2023

The rapid demise of Silicon Valley Bank put an unwelcome spotlight on the financial position of many small biotechnology companies that relied on the storied lender. But to the people who form and build startups, SVB’s collapse is a sidebar […]

March 14, 2023

The panic that accompanied the collapse of the biotechnology sector’s bank of choice ebbed Sunday when the federal government moved to protect all depositors of Silicon Valley Bank. The muscular intervention allayed the fears of the many young biotech companies […]

March 13, 2023

In less than 48 hours, the bank many young biotechnology companies relied on for years was gone. On Friday, the Federal Deposit Insurance Corp. closed Silicon Valley Bank, culminating a stunning collapse that triggered alarms throughout the sector. SVB was […]

February 14, 2023

Kevin Parker is an expert in genomics, immuno-oncology and computational biology. A Ph.D. scientist from Stanford University, he has helped author research in prestigious journals like Science, Nature Medicine and Cell. But two years ago, when Parker was working with […]

January 27, 2023

While global macroeconomic uncertainty continues to impact financing, the pharma industry has focused on UK biotechs to strengthen product pipelines. But with difficult public markets and low investor appetite, new launches were almost unseen in 2022, with public markets contributing […]

January 25, 2023

Goulburn, Dar and Li believe a shift is underway in biotech. The three friends, who have helped build new companies with their respective firms for about a decade, are convinced the search for new drugs is becoming increasingly digitized. Artificial […]